First-line treatment with HDACis plus tislelizumab combined with chemotherapy in advanced NSCLC: a single-arm phase II study
HDAC抑制剂联合替雷利珠单抗和化疗一线治疗晚期非小细胞肺癌:一项单臂II期研究
期刊:Oncologist
影响因子:4.2
doi:10.1093/oncolo/oyaf155
Wang, Lijie; Gao, Ming; Wang, Ting; Cui, Pengfei; Chen, Guangying; Han, Xiao; Ma, Zhiqiang; Yang, Wenyu; Jing, Fangfang; Ma, Junxun; Zhang, Fan; Tao, Haitao; Hu, Yi